ClinicalTrials.gg
Active, not recruitingNCT06447623Updated Sep 25, 2026

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

A Phase 3 interventional study of Apatinib and CDK4/6 Inhibitor in Advanced Breast Cancer and HR+/HER2- Breast Cancer, sponsored by Fudan University. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know · 9 judgments

Updated Sep 25, 2026Now Active, not recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing apatinib in Breast Neoplasms — 11 open to participants now, 15 under way, 6 of them phase 3. apatinib · Breast Neoplasms.

Planned enrollment
10th of 27
184 · median 80
Started
2024
with 4 others
Phase 3
6 of 27
3 open now
Primary completion
2027-02
later than 8 of 14 live
Registered
23rd of 27
by date
Lead sponsor
6 of 27
Fudan University

Among the 27 studies testing apatinib in Breast Neoplasms, this one is the 10th largest by planned enrollment, is one of 5 that started in 2024, is one of 6 in phase 3, reaches primary completion later than 8 of the 14 other live ones, and was the 23rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 27 studies testing apatinib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing apatinib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, controlled, open-label, phase III study to explore the efficacy and safety of Apatinib in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF4 subtype of advanced breast cancer. The study was used to explore the efficacy of Apatinib in combination with standard endocrine therapy.

03

Conditions studied

  • Advanced Breast Cancer
  • HR+/HER2- Breast Cancer

Browse trials for

Keywords

  • HR+/HER2- breast cancer
  • Advanced Breast Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:
  • Patients need to meet all of the following conditions

    • Patients must be ≥18 and ≤ 75 years of age;
    • confirmed breast cancer is HR+/- breast cancer (IHC ER >10%, or/and PR>10%, HER 0 OR +, if HER2++, FISH negative);
    • SNF4 subtype definition: SNF4 subtype confirmed by digital pathology of H\&E sections;
    • Locally advanced breast cancer (radical local therapy is not possible) or breast cancer (without using adjuvant CDK4/6 inhibitors in the past, or one year after CDK4/6 inhibitor therapy has ended);
    • No prior therapy (chemotherapy, targeted therapy, etc.) for advanced or metastatic breast cancer;
    • Patients with at least one that has not previously received radiation therapy and can be evaluated repeatedly according to 1.1;
    • The functions of the main organs are basically normal, and the following conditions are met:

      1. Blood routine examination standards should meet: HB≥90g/L (no blood transfusion within 14 days); ≥1.5×109/L; ≥75×109/L;
      2. Biochemical examination shall meet the following standards: ≤1.5× (upper limit of normal value); and AST≤3 x ULN; In case of liver metastasis, ALT and AST≤5×ULN; Serum Cr ≤1.5×ULN, endogenous > 50ml/min (Cockcroft-Gault formula);
    • performance status 0 or 1; The expected survival is more than 3 months;
    • Fertile female is required to use a medically approved during study treatment and for at least 3 months after the last use of the study drug;
    • Patients voluntarily join the study, sign the , have good compliance, and cooperate with follow-up.

Exclusion Criteria:

  • Patients with any of the following conditions were excluded from the study

    • Patients with central nervous system metastasis out of control (symptoms need to use or mannitol).
    • A history of or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia;
    • Radiotherapy, chemotherapy, surgery, other targeted therapy, and immunotherapy for advanced HR+/HER2- breast cancer within 4 weeks before the first administration of drugs used in this study.
    • Pregnant or lactating patients;
    • Other within the previous 3 years, excluding cured skin basal cell carcinoma and cervical carcinoma in situ;
    • Significant comorbid medical conditions, including mental illnesses that the investigator or sponsor believes would adversely affect the patient\'s participation in the study;
    • Allergic physique, or known allergic history of the drug components of this program; Or allergic to other monoclonal antibodies;
    • The investigator does not consider the patient suitable for participation in any other circumstances of the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Arm-A

    Apatinib combined with cdk4/6i and Endocrine therapy.

    Drug: Apatinib · Drug: CDK4/6 Inhibitor · Drug: Aromatase inhibitor and Fulvestrant

  • Active comparator
    Arm-B

    cdk4/6i and Endocrine therapy.

    Drug: CDK4/6 Inhibitor · Drug: Aromatase inhibitor and Fulvestrant

Interventions

  • Apatinib is a kind of TKI inhibitor.

  • DrugCDK4/6 Inhibitor

    Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.

  • DrugAromatase inhibitor and Fulvestrant

    Drug pages: Aromatase inhibitorsStudies of Aromatase inhibitorsAromatase inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FulvestrantStudies of FulvestrantFulvestrant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    The interval from randomization until the first occurrence of disease progression (according to RECIST 1.1) or death from any cause, which ever occurs first.

    Time frame: Approximately 5 years

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    CBR is the total percentage of participants who achieved a complete response, partial response, or had stable disease for 6 months or more.

    Time frame: Approximately 5 years

  2. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have a complete response (CR) or partial response (PR) based on BICR and investigator assessment using RECIST 1.1.

    Time frame: Approximately 5 years

  3. Overall Survival (OS)

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Approximately 5 years

  4. Safety and tolerability

    Number of adverse events according to NCI-CTCAE Version 5.0 per each treatment arm.

    Time frame: Approximately 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 31 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 31 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Start moved once since we started tracking on Sep 25, 2026: Feb 2024 → Jun 2024, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2024
First posted
Jun 7, 2024
StartActual
Jun 11, 2024was Feb 2024
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2029
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 25, 2026
Sites
1 site added, 1 site removed
Show site
  • Fudan University Shanghai Cancer Center · Shanghai, China
Show 1 removed
  • Fudan University Shanghai Cancer Center · Shanghai, China
Sep 25, 2026
Start date
Feb 1, 2024→Jun 11, 2024
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Fudan University Shanghai Cancer Center · Shanghai, China
    Show 1 removed
    • Fudan University Shanghai Cancer Center · Shanghai, China
    Start date Feb 1, 2024→Jun 11, 2024
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06447623
Lead sponsor
Fudan University
Responsible party
Zhimin Shao (Director of General Surgery of Fudan Shanghai Cancer Center, Fudan University) — Principal investigator
First posted
Jun 7, 2024
Start date
Jun 11, 2024
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apatinib

Start the discussion